Seeking Alpha

Repros Therapeutics jumps as Androxal meets endpoints

  • Repros Therapeutics (RPRX) soars 26% premarket.
  • Androxal topline results from ZA-302 (pivotal efficacy) and ZA-300 (six-month safety) show the secondary hypogonadism treatment met both primary endpoints and is generally well tolerated.
  • ZA-302 results are "almost identical" to the first pivotal efficacy study. (PR)
  • Expect an NDA in mid-2014.
  • RPRX says it expects to have "launch drug product available for an anticipated approval during 2015."
  • It's worth noting that back in July, BofA's Steve Byrne said peak 2022 sales could reach $450M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|